§ 13F · FUND PROFILE
Royalty Pharma Sub-Manager, LLC.
AUM · $484M (13F)Positions · 8Turnover · n/a · Q2Filed · Aug 14, 2026
CONCENTRATION
n/a
Top 10 holdings
NEW BUYS
0
+$115M deployed
EXITS
0
No exits
SECTOR SHIFT
n/a
No prior quarter data
§ 01 · TOP HOLDINGS
The book · Q2 2026
FILED AUG 14, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q2 |
|---|---|---|---|---|---|---|
| 1 | CYTK | CYTOKINETICS, INC | 980K | $84M | — | — |
| 2 | CYTK | CYTOKINETICS, INC | 980K | $84M | — | +100% |
| 3 | ZBIO | ZENAS BIOPHARMA, INC. | 2.39M | $61M | — | ±0% |
| 4 | BCAX | ZENAS BIOPHARMA, INC. | 2.39M | $61M | — | NEW |
| 5 | KLRA | KAILERA THERAPEUTICS | 2.46M | $54M | — | NEW |
| 6 | KLRA | KAILERA THERAPEUTICS | 2.46M | $54M | — | — |
| 7 | BHVN | BIOHAVEN LTD | 2.94M | $44M | — | +100% |
| 8 | BHVN | BIOHAVEN LTD | 2.94M | $44M | — | — |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE ROYALTY SIGNAL
AC read
Royalty Pharma Sub-Manager, LLC is a institutional fund managing $484 million in assets. The fund runs a focused portfolio of just 8 positions.
Read the full dossier →